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Proton radiotherapy should be further developed in Poland
Adam Maciejczyk1, Aleksandra Sztuder2
Proton radiation therapy needs to be further developed in Poland by virtue of both epidemiological considerations 
and because this type of radiation exhibits very advantageous biological and physical properties. The underlying 
benefit of such therapy is to make lower integral radiation dose delivered to structures beyond a given target area, 
including critical organs, resulting in reduced toxicities for patients. Of somewhat less import is the improvement in 
dose distributions for target areas (vs photons), which can potentially bring about a better local control. As a result, 
proton radiotherapy is mainly indicated for paediatric cases, where any development of complications is most likely 
because of the long lifetimes and the heightened radiosensitivity of healthy tissues. The most recent studies also 
show that certain subpopulations of patients can benefit from proton beam radiotherapy in cases of widespread 
cancers such as from the lung or breast. A further advantage is found after conducting a cost-effectiveness analysis 
whereby proton beam radiotherapy was demonstrated as a cost-effective procedure, with both lowered costs for 
treating complications and indirect costs. By the term ‘development’ as used herein, it is understood that there is  
a need to open another proton therapy centre in Poland; this question however being left open in the presented 
article. Nevertheless, before taking such a high-level decision, the following requires consideration: the working 
experience garnered by the existing Cyclotron Centre at Bronowice (CCB), outcomes from current prospective clinical 
trials and, above all, delivering appropriately managed and coordinated oncological care for cancer patients in Poland 
regarding multi-centre collaboration between specialists. 
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Over many years, proton beam radiotherapy has been 
used as an alternative to photon radiation therapy. In global 
terms, centres for proton radiotherapy are undergoing dy-
namic development [1]. Regarding Poland, this technique 
was first used in Cracow in 2011 for treating patients suf-
fering from ocular melanoma, where an ischronic cyclo-
tron (AIC-144) was used with accelerated protons of up to 
60 MeV energy; this work being a collaboration between 
the Ophthalmology and Oncology Clinic of the Universi-
ty Hospital in Cracow, the M. Skłodowska-Curie Memorial 
Centre for Oncology Institute and the H. Niewodniczański 
Memorial Institute of Nuclear Physics at the Cracow branch 
of the Polish Academy of Sciences (PAN) [2]. For the latter, 
construction of a Cyclotron Centre at Bronowice (CCB) was 
started in March 2011, whereupon the Centre was cere-
monially opened on the 15th October 2015; a Proteus-235 
isochronous cyclotron having been installed, achieving 
a proton beam of 70-230 MeV [3]. 
On 27th May 2015, a report was published by the Pro-
ton Radiotherapy Team concerning the use of this tech-
nique for treating cancers outside the eyeball in Poland 
[4], where indications were based on analysing the latest 
literature that included proposals put forward by the afore-
said team from the Cracow branch of the M. Skłodowska-
Curie Memorial Centre for Oncology Institute [4]. On June 
15th 2016, legislation was passed by the Polish Minister 
for Health on the basis of Recommendation No. 85/2015 
prepared by the Director of the Agency for Assessing Medi-
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cal Technologies and Tariffs made on 29th October 2015 
for sanctioning refundable healthcare treatment regard-
ing the use of ’Proton Radiotherapy for treating cancers 
outside the eyeball’ as a guaranteed healthcare benefit 
in hospital treatment [5]. 
In June 2016, the Lesser Poland (Małopolska) Region-
al Branch of the NFZ (National Health Fund) announced 
a tender for tumour treatment by means of proton beams 
and from 30th September 2016, proton radiotherapy became 
available as a healthcare service in Poland delivered by the 
Centre for Oncology Institute in Cracow in agreement with 
the Bronowice Cyclotron Centre [3]. Indeed on the latter’s 
website, it was officially reported that the first patient had 
undergone proton radiotherapy between 3rd November to 
27th December 2016 [3] and was the result of a collabora-
tion between the aforementioned institutes (i.e. the Cracow 
branch of the M. Skodowska-Curie Memorial Centre for 
Oncology Institute and the Cyclotron Centre at Bronowice IFJ 
PAN) [3]. An obvious question thus arises: should proton ra-
diotherapy be further developed in Poland? Firstly however 
within this context, the word ‘develop’ requires clarification. 
Does it mean that training medical personnel is needed 
(including oncologists and medical physicists) along with 
conducting clinical trials using proton beams, and whether 
a second proton therapy centre should be established in Po-
land? It is the author’s conviction that proton radiotherapy 
should undoubtedly be developed as is dictated by epide-
miological circumstances and the exceptional biological and 
physical properties of this technique, which affords better 
protection to healthy organs as well supporting evidence 
from dosimetric studies and partly also from clinical trials. 
Furthermore, the cost-effectiveness of proton therapy is 
well recognised in the literature.
At present, increasing numbers of proton therapy cen-
tres have been observed worldwide; more than 90 such 
centres are estimated by 2020 [1]. This increase is linked to 
demand; one hadron therapy centre, (NB. protons being 
classified as hadrons), is recommended for a 8–10 million 
population [6]. Predictions have been made for the number 
of patients requiring this therapy per head of population 
where it is estimated that 20,000 patients per every 10 mil-
lion will annually require photon radiotherapy, of whom 
2,400 (about 12%) should be of the proton kind [7]. The 
number of cancer patients in Poland is projected to increase 
from currently 310,000 to 350,000 by 2025; such cases con-
stitute the second leading cause of mortality in Poland and 
the European Union [8]. These increases will in turn, thus 
further increase the number of patients requiring proton 
radiotherapy. 
Undoubtedly the advantages of protons can ascribed 
to their biological properties: they possess a higher Rela-
tive Biological Effectiveness ratio (RBE) than photons, by 
1.1 to 1.2, as estimated by Pagnetti et al. [9]. This advan-
tage is translated to the target irradiation area, but not to 
any critical organs. Intriguing reports have been published 
concerning a proposed advantage for using protons at the 
subcellular level within DNA and beyond DNA, together 
with at the cellular, microenvironmental and tissue levels 
[10]. At the subcellular level, qualitative and quantitative 
advantages of protons have been propounded for induc-
ing double-stranded DNA breaks and clustered lesions (CL), 
(i.e. regions with many and varied breaks located on one or 
two opposite DNA strands), epigenetic changes (possible 
proton-induced hypermethylation) and a greater efficiency 
(by 50%) for inducing reactive oxygen species (ROS) in clo-
nogenic cells [10].
At the cellular level, proton beam irradiation may be 
more effective than photons for inducing apoptosis (by 
elevated mRNA expression of pro-apoptotic genes) and 
protons have potentially more varied effects (vs photons) on 
modulating the cell cycle [10]. Within tissue and the micro-
environment levels, neoangiogenesis becomes inhibited i.e. 
reduction of pro-angiogenic proteins and pro-inflammatory 
factors, as well as migration and invasion becoming inhib-
ited, (e.g. inter alia inhibition of metalloproteinases), [10]. 
In themselves however, protons possess unique physical 
characteristics that include: low entrance dose, enhanced 
by a ‘Spread Out Bragg Peak’ (SOBP), a sudden rise followed 
by a sudden drop in dose (the so-called Bragg Peak), no 
exit dose and small amounts of lateral scattering [11]. The 
primary benefit of proton beam irradiation is therefore 
a smaller integral dose, (for structures outside target areas 
that include critical organs), which is associated with re-
duced toxicity, including that for secondary cancers.
Improvements in dose distribution in the target area is 
of lesser significance, as compared to photons, excepting 
potential improvements for local control (and consequently 
for instance, in overall survival). Because of such features, 
attempts are made for escalating the dose and for imple-
menting hypofractionated schemes. In order that the unique 
characteristics of protons be demonstrated, the example 
of dosimetric analysis for paediatric patients can be used, 
which reveals that in most cancer cases, reduced doses 
are employed to critical organs (regarding moderate and 
near-maximum dose — D2%) as well as smaller target vol-
umes that are subjected to proton irradiation [12]. Indeed, 
proton therapy is a model example of the basic principle of 
radiological protection; ALARA (as low as reasonably achiev-
able), which requires that minimal doses of ionising radia-
tion should be delivered when socio-economic factors are 
taken into consideration. It should be noted that in 2001, 
Dr Herman Suit presented the four basic tenets of proton 
radiotherapy:
 — no advantage to any patient for any irradiation of any 
normal tissue exists. Normal tissues are defined here as 
tissues not suspected of involvement by tumor;
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 — direct radiation complications never occur in unirradi-
ated tissues;
 — that a smaller treatment volume is superior is not a me-
dical research question;
 — one may only investigate the magnitude of the gain or 
the cost of achieving that gain [13].
Any therapeutic decisions should be taken on evidence-
based medicine (EBM). Proton radiotherapy studies primarily 
consist of a large number of dosimetric analyses, modelling 
studies (based on radiobiological models with estimates 
of the Normal Tissue Complication Probability; NTCP) and 
clinical trials. It is noteworthy that Phase III randomised 
trials are necessary for proton radiotherapy to be more 
widely applied. This is reasonable, although developments 
in proton radiotherapy should not be halted, keeping in 
mind that only 10% of oncological recommendations are 
based on Level 1 evidence from clinical trials [14]. Some 
authors even consider that Phase III studies using proton and 
photon therapies are unethical [15], especially for paediatric 
patients; but surely a 0% dose is equivalent to 0% complica-
tions. Of course there is a need for follow-up which includes 
dosimetric analyses, modelling studies, clinical trials (also 
pragmatic clinical trials; PCTs) together with cost-effective-
ness analyses. A highly interesting, but labour intensive idea 
is a web-based platform prototype that provides advice on 
choosing the radiation therapy (i.e. protons vs photons) 
for head and neck cancers that includes a comparison of 
histograms, possible toxicities and cost-effectiveness [16]. 
The best documented clinical trial when applying pro-
ton radiotherapy is on paediatric patients, (its use predomi-
nating in these cases), where smaller integral doses are 
employed which, given the potentially long survival time of 
convalescents and the likelihood of developing complica-
tions, become crucial to this age group. In cases of central 
nervous system (CNS) cancers in children, using proton 
radiotherapy is justified especially to those cases requir-
ing irradiation of the cerebrospinal axis, pinealoblastoma, 
other primitive neuroectodermal tumours (PNETs; currently 
classified in 2016 according to the WHO as CNS cancers but 
not otherwise classified), anaplastic ependymoma (with 
documented dissemination into the cerebrospinal fluid) 
and choroid plexus carcinoma [17]. 
Using proton radiotherapy sounds appropriate and is 
confirmed by studies evaluating the effectiveness of this 
treatment and, above all else, its safety i.e. reducing the risk 
of adverse events [17, 18]. The efficacy studies for proton 
beam radiotherapy on CNS cancers indicate high rates of 
overall survival [17]. Reducing the number of complications 
to healthy organs has been confirmed in numerous dosi-
metric and modelling studies showing decreased risks of: 
cardiac toxicity [19], premature radiotherapy-related ovarian 
failure [20], ototoxicity [21] or cognitive impairment [22]. 
Indeed, the first clinical data has now emerged on improved 
Health-Related Quality of Life (HRQoL) in patients after re-
ceiving proton irradiation in childhood compared to photon 
therapy [23]. It appears there is unequivocal evidence sup-
porting the use of proton therapy for low-grade gliomas in 
children in terms of dose distribution to critical organs and 
toxicity [17, 24]. Indications on using proton radiotherapy for 
cases of highly differentiated gliomas should be established, 
given that they are the most commonly diagnosed brain 
tumours in children and thus constitute the most common 
cause for employing brain radiotherapy to this age group [17]. 
The value-added benefit of proton beam radiotherapy is 
also increased when cases of soft tissue sarcoma [25], chor-
doma and chondrosarcoma [26] and retinoblastoma [27] 
are diagnosed. 
Out of the aforementioned diagnoses of childhood can-
cer, the Director of the Medical Technology Assessment and 
Tariff Assessment Agency recommends NFZ-funded proton 
radiotherapy for brain cancers, (that require irradiation of the 
cerebrospinal axis and selected highly differentiated glio-
mas that only include those cases where a significant benefit 
is expected of critical organ sparing compared to photon 
radiotherapy), as well as soft tissue sarcoma (located at the 
the base of the skull, paramaeningeal and paraspinal) [28]. 
A widely known radiobiological dictum applicable in paedi-
atrics is the high intracellular radio-sensitivity regarding the 
CNS. The means for reducing doses to the CNS structures is 
thus provided when using proton radiotherapy which should 
be taken into account whenever extending the aforemen-
tioned indications becomes necessary, particularly for all 
cases of low- grade gliomas [17, 24], germ cell tumours [29] 
or ependymomas [30] or craniopharyngiomas [17], as well 
as for local recurrences requiring reirradiation within the 
CNS or head and neck regions.
An important benefit of using protons is also in reduc-
ing the risk of the so-called secondary tumours by over 2 
or even 15 times according to dosimetric and modelling 
studies [31, 32]. However, based on the USA SEER data base 
(Surveillance, Epidemiology and End Results) regarding clini-
cal studies, this risk is 5.2% when using proton radiotherapy 
but 7% for photon therapy [33]; with the proviso that the 
observation period was relatively short. 
Indications for therapy in adult patients are more limited, 
where although there are many dosimetric and modelling 
studies reported in the literature, there are fewer worth-
while clinical studies published. The recommendations of 
the Director of the Medical Technology Assessment and 
Tariff Assessment Agency concerning adult cancer include 
chordoma and chondrosarcoma of the base of the skull and 
paraspinal region, paranasal sinus tumors and low-grade 
gliomas [28]. Supporting scientific evidence, similar to child-
hood cancers, is equally applicable for favourable irradiation 
efficacy as likewise are the significantly reduced adverse 
reactions [34–38]. It seems justified in this case to consider 
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extending the indications to include other head and neck 
tumours near the base of the skull, thereby enabling the 
neighbouring and radiosensitive structures of the CNS and 
vasculature to be protected [39]. 
The accrued benefit of proton beam treatment for tu-
mours of the head and neck can also be used by patients 
being at high risk of oral mucosal complications. With the 
aid of proton beams, very satisfactory local responses were 
achieved with minimal toxicity; patients underwent radio-
chemotherapy up to a dose of 70 Gy at 2.12 per fraction, 
where the treatment response was 93.3% with minimal 
toxicity (0% of grade G2 mucositis) [40]. In cases of CNS 
cancers, low-grade gliomas, proton radiotherapy is publi-
cally refundable in instances where significant benefits 
can be predicted through critical organ sparing when 
compared to photon radiotherapy [28]. According to the 
literature data, indications for using proton irradiation 
should be considered in cases of atypical meningiomas, 
especially those located near critical organs [41]. It should 
be pointed out however, that recognised indications for 
proton irradiation in adults therefore include somewhat 
rare cancers. An obvious question seems to be whether 
proton beam radiotherapy can improve the therapeutic 
index for the most common tumours?
A study by Doyen et al. determined those diagnoses 
where dose reductions could be delivered to critical organs 
using proton beam irradiation; these being: non-small cell 
lung carcinomas, cancers of the breast (with nodal irra-
diation), oesophagus, pancreas, bile ducts, liver, prostate, 
rectum, anus, cervix, head and neck tumours (the prepon-
derance of using protons is not necessarily repeated in 
each instance as comparing plans is required for each case), 
pleural mesothelioma, Hodgkin’s lymphoma and retroperi-
toneal sarcomas [42]. It seems that there is a subpopulation 
of patients that can especially benefit from proton beam ra-
diotherapy in cases of widespread cancers such as the lung, 
breast or oesophagus. In the former, the postulated benefit 
of using proton radiotherapy in lung cancer is that the dose 
can be escalated without increasing cardiopulmonary toxic-
ity [43] along with a potential for extending patient survival 
by reducing pulmonary toxicity, oesophageal toxicity and 
lymphopenia. 
At present, a randomised Phase III RTOG 1308 study 
is ongoing which compares patient overall survival after 
radiotherapy between proton and photon beam modes 
for cases of non-small cell lung cancer (Stages II to IIIB). 
Using proton radiotherapy for breast cancer may appear 
controversial, yet there are sufferers that may thereby gain 
benefit, of whom there are principally two such populations: 
patients vulnerable to cardiac complications (e.g. young 
women with cancer of the left breast without any chances of 
reducing the 5 Gy dose to the heart and who also suffer from 
existing cardiac disease or are undergoing combination 
therapy — anthracyclines and trastuzumab) and secondly, 
those patients vulnerable to secondary tumours (e.g. < 60 
years age and having a large irradiated volume), [44]. 
Another study, a Phase II NCT01758445 trial, is currently 
ongoing to investigate rates of adverse events following 
proton radiotherapy in patients suffering from stage II to 
III breast cancer requiring whole breast or thoracic cavity 
irradiation together with that of the locoregional lymphatic 
system as regards cardiac toxicity and secondary tumours 
10 and 15 years after proton radiotherapy had been admin-
istered. In oesophageal cancer, a benefit is postulated for 
decreasing toxicity (cardiac, lung, kidneys and liver) where 
a dose escalation study (hyperfractionated proton therapy 
at doses 50.4 to 78 Gy) showed no increased toxicities with 
the rate at 5 year follow-up being 84.4% [45]. From 2012, 
patients are being recruited to a Phase II NCT 01512589 study 
which compares IMRT (Intensity Modulated Radiation Thera-
py) photon therapy with proton radiotherapy in oesophageal 
cancer in combination treatment with chemotherapy, taking 
into account safety and therapeutic efficiency.
Because of how the dose is deposited, proton radio-
therapy may be a valuable, and indeed the only means of 
re-irradiation, particularly in cases of recurrence localised 
within the brain or head and neck regions [46, 47]. More 
long-term observations are however required, but above 
all else prospective studies are needed. 
The concluding argument supporting the use of proton 
radiotherapy is cost-effectiveness. All radiotherapy requires 
expensive equipment and highly qualified staff, but in it-
self, it is not an expensive treatment and consumes only 
about 5% of a running oncology budget [2]. A Swiss study 
has found that the cost of proton radiotherapy is 2.4 times 
higher than IMRT [48]. 
It can be expected that over time, this can be reduced 
to 2.1 or even 1.7 times, however proton radiotherapy will 
probably always remain more expensive that photon ther-
apy [48]. There are two vital economic measures used for 
analysing the efficiency of medical procedure outcomes: 
the cost of obtaining an extra ‘Quality-Adjusted Life Year’ 
(QALY) or an extra ‘Life Year Gained’ (LYG). As a general rule, 
if the cost of a given intervention is less than 44,665 EURO 
(i.e. $50,000) for an extra LYG or QALY then a favourable 
price/quality ratio is achieved [1]. Nonetheless in Holland 
for example, societal acceptance for enabling an extra LYG 
comes to even 80,000 EURO. In Poland, the Health Cost 
Index obtained is compared with the so-called Profitability 
Threshold i.e. an outcome which calculates, at our country’s 
GDP level, the maximum cost of a new treatment required 
for achieving a Unitary Health Effect, (in this case 1 LYG 
or 1 QALY), compared to those treatments in current use, 
which should not exceed the GDP per capita by 3 times 
[28]. In 2015, such threshold estimates were 119,577 PLN 
(i.e. 3 × 39,859 PLN), [28]. At the same time, when assum-
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ing average expenses, the cost of a single patient treated 
abroad ranges from 21,854 PLN to 581,894 PLN (mean of 
140,202 PLN), whereas the estimated cost in Poland, accord-
ing to the Health Problem Card data is 130,219.53 PLN [28]. 
It should be noted that in performing an economic analy-
sis, all cost elements of any further treatment are included 
whenever treating photon radiotherapy toxicity is required, 
for example ototoxicity in cases of medulloblastoma [49], 
cardiotoxicity and the risk of secondary tumours as well as 
indirect costs such as: absenteeism from work, presentee-
ism (coming to work despite ill health; associated with both 
lowered productivity and work quality), premature death 
and being incapacitated together with absenteeism and 
presenteeism of the carers. 
It should also be stressed that the lower the exposure 
of healthy tissue to irradiation achieved in proton radio-
therapy may permit hypofractionation to be increasingly 
used, which represents a very cost-effective means of dose 
delivery and raised local tumour control resulting in de-
creased costs for reirradiation, salvage surgery and palliative 
chemotherapy. Furthermore, the operative life-span of pro-
ton radiotherapy equipment is 30 years and over, whereas 
it is shorter for photon accelerators [50]. According to the 
literature, proton beam radiotherapy offers cost-effective 
treatment in diagnosed cases of: medulloblastoma, selected 
patient groups with locally advanced lung cancer and cer-
tain high-risk cancers of the head and neck [1]. 
Concluding therefore, proton radiotherapy needs to be 
developed because of increased cancer rates (that translate 
into increased subpopulations of patients requiring proton 
beam radiotherapy) and the need to expand the list of diag-
noses that are recommended to secure guaranteed benefits, 
(based on clinical study data and economic analyses). This 
diagnoses list should include the following: CNS tumours in 
children (mainly ependymomas, germ cell cancers and low-
grade gliomas), whilst for adults atypical meningiomas, head 
and neck cancers localised to the base of the skull as well as 
selected breast, lung and oesophageal cancers. Such devel-
opments should foremost be understood to mean an urgent 
need to create a skilled workforce inter alia doctors, whereby 
the process of qualifying patients for proton radiotherapy 
could take place at the level of regional health centres.
Is it thus appropriate to open another proton radiother-
apy centre and is the epidemiological evidence sufficient to 
justify this? These questions we leave open.
Before replying to these questions I think one should 
first consider whether oncological treatment is sufficiently 
well organised in Poland to cope, particularly when it comes 
to collaboration between specialists from multi-centres and 
with coordinating healthcare for cancer patients. I personally 
believe that such patients deserve access to modern thera-
pies, but in cases where high-cost therapies are needed, (like 
proton radiotherapy), then the whole process of treatment 
should be very well planned including taking into considera-
tion close patient access to cancer units that are experienced 
in surgical treatment and systemic care for those patients that 
can most benefit. It should be remembered that the basis of 
cancer treatment is combined therapy and it is necessary to 
constantly strive for improving the functioning of the oncol-
ogy treatment system in which, increasingly, proton radio-
therapy is occupying a more justifiable/prominent position. 
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